Drug Candidate for Treatment of Pain
APD371, an orally available agonist of the CB2 receptor, is an internally discovered investigational drug candidate that Arena is exploring for potential development in several indications, including pain. This compound, through its selectivity, is designed to provide pain relief without psychotropic effects and without the potential for dependence or abuse.
We have initiated a randomized, open-label and parallel Phase 2a clinical trial to evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD371.
|Drug Candidate||Disease Area||Target||Status||Retained Rights|
|APD371||Pain||CB2 Agonist||Phase 2a Ongoing||Worldwide|
|Status||Phase 2a Ongoing|
APD371 has not been approved by the US Food and Drug Administration or any other regulatory agency.